InsiderTrades.com logo
James N. Topper net worth and biography
  • Phone
  • Email
  • Website

James Topper Biography and Net Worth

Director of NewAmsterdam Pharma

William (Will) H. Lewis is the Chair and Chief Executive Officer of Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on serious and rare diseases. He joined Insmed in 2012 as President and CEO and as a member of the board of directors, and became Chair of the board in 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and he previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government.

Will holds a bachelor of arts degree cum laude from Oberlin College, as well as a master of business administration and a juris doctor with honors from Case Western Reserve University. Will is a member of the board of trustees of Case Western Reserve University and a member of the board of trustees of BioNJ, the life sciences association for New Jersey.

What is James N. Topper's net worth?

The estimated net worth of James N. Topper is at least $70.45 million as of March 4th, 2025. Mr. Topper owns 3,012,434 shares of NewAmsterdam Pharma stock worth more than $70,445,769 as of March 17th. This net worth estimate does not reflect any other investments that Mr. Topper may own. Learn More about James N. Topper's net worth.

How do I contact James N. Topper?

The corporate mailing address for Mr. Topper and other NewAmsterdam Pharma executives is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. NewAmsterdam Pharma can also be reached via phone at 352062971 and via email at max.nowicki@frazierhealthcare.com. Learn More on James N. Topper's contact information.

Has James N. Topper been buying or selling shares of NewAmsterdam Pharma?

During the last quarter, James N. Topper has bought $84,185.10 in NewAmsterdam Pharma stock. Most recently, on Tuesday, March 4th, James N. Topper bought 4,005 shares of NewAmsterdam Pharma stock. The stock was acquired at an average cost of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. Learn More on James N. Topper's trading history.

Who are NewAmsterdam Pharma's active insiders?

NewAmsterdam Pharma's insider roster includes Juliette Audet (Insider), Michael Davidson (CEO), Johannes Kastelein (Insider), Louise Kooij (CAO), and James Topper (Director). Learn More on NewAmsterdam Pharma's active insiders.

Are insiders buying or selling shares of NewAmsterdam Pharma?

During the last twelve months, NewAmsterdam Pharma insiders bought shares 4 times. They purchased a total of 18,538 shares worth more than $369,041.40. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 832,206 shares worth more than $19,296,828.63. The most recent insider tranaction occured on March, 4th when CAO Louise Frederika Kooij sold 150,000 shares worth more than $3,055,500.00. Insiders at NewAmsterdam Pharma own 19.5% of the company. Learn More about insider trades at NewAmsterdam Pharma.

Information on this page was last updated on 3/4/2025.

James N. Topper Insider Trading History at NewAmsterdam Pharma

See Full Table

James N. Topper Buying and Selling Activity at NewAmsterdam Pharma

This chart shows James N Topper's buying and selling at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$84kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

NewAmsterdam Pharma Company Overview

NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $23.34
Low: $23.12
High: $23.77

50 Day Range

MA: $21.95
Low: $17.53
High: $26.04

2 Week Range

Now: $23.34
Low: $15.19
High: $27.29

Volume

1,435,402 shs

Average Volume

493,543 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A